Patents Assigned to Texas Health Science Center
  • Publication number: 20140045950
    Abstract: The invention provide herein provides for a targeted drug delivery vehicle compositions, methods of manufacture, and methods of treatment for therapeutic applications.
    Type: Application
    Filed: August 7, 2013
    Publication date: February 13, 2014
    Applicants: National Institutes of Health, University of North Texas Health Science Center
    Inventors: Andras G. Lacko, Alan T. Remaley
  • Patent number: 8575230
    Abstract: Environmentally-friendly alternatives to organometallic antifoulants that are efficacious at preventing biofouling by organisms such as the zebra mussel. Preferred antifoulant compositions utilize compounds having a Lipophilic-Amide-Spacer-ElectroNegative (“LASEN”) structural motif, such as capsaicin, and compounds having a TetraHydroCannibinoid (“THC”) structural motif. The antifoulant compositions are non-toxic, and effective.
    Type: Grant
    Filed: April 16, 2008
    Date of Patent: November 5, 2013
    Assignees: University of North Texas Health Science Center at Fort Worth, The Board of Regents of the University of Texas System
    Inventors: John A. Schetz, Robert F. McMahon
  • Publication number: 20130274136
    Abstract: The invention relates to point of care diagnostic disposables, devices, methods, and systems for diagnosing or predicting prostate cancer. The present invention employs biomarker specific reagents in disposable cassettes or lab cards for use as analyzers, as well as software to evaluate and report test results. The system promises to improve point of care in vitro diagnostics.
    Type: Application
    Filed: November 11, 2011
    Publication date: October 17, 2013
    Applicants: UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, WILLIAM MARSH RICE UNIVERSITY
    Inventors: John T. McDevitt, Nicolaos Christodoulides, Pierre N. Floriano, Ian Thompson
  • Patent number: 8389496
    Abstract: The present invention provides methods and kits for diagnosing and treating glaucoma.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: March 5, 2013
    Assignees: Novartis AG, North Texas Health Sciences Center, University of
    Inventors: Abbot F. Clark, Robert J. Wordinger
  • Publication number: 20120207857
    Abstract: The present invention includes compositions and method to improve the therapeutic index of anti-cancer agents using a novel anti-cancer agent and a modulator or potentiator thereof
    Type: Application
    Filed: April 4, 2012
    Publication date: August 16, 2012
    Applicant: University of North Texas Health Science Center at Fort Worth
    Inventors: Wolfram Siede, Rouel S. Roque
  • Patent number: 8163692
    Abstract: Methods of preparing a proteoliposome comprise the step of contacting a liposome with an effective portion of RalBP1 to create a proteoliposome. RalBP1 is effective for the protection and treatment of mammals and the environment against the accumulation of toxic compounds, and prevents accumulation of one or more toxic compounds, reduces the concentration of toxic compounds, and protects against further contamination with one or more toxic compounds. In addition, RalBP1 is effective for the protection and treatment of mammals against the effects of ionizing radiation.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: April 24, 2012
    Assignee: University of North Texas Health Science Center of Fort Worth
    Inventors: Sanjay Awasthi, Sharad S. Singhal
  • Patent number: 8159676
    Abstract: The present invention includes methods for ratiometric detection of analytes by surface plasmon coupled emission detection that includes disposing a target on the metal layer of a surface plasmon resonance detection system; coupling a first analyte to a first fluorescent dye and a second analyte to a second fluorescent dye; contacting the first and second analytes to the target on the surface plasmon resonance detection system; and measuring the intensity of a first and a second surface plasmon resonance enhanced fluorescence emission ring, wherein the first and second rings, respectively, quantitatively represents the amount of first and second analyte within 50 nanometers of the metal surface.
    Type: Grant
    Filed: January 20, 2009
    Date of Patent: April 17, 2012
    Assignee: University of North Texas, Health Science Center at Fort Worth
    Inventors: Zygmunt Gryczynski, Ignacy Gryczynski, Evgenia Matveeva, Julian Borejdo
  • Publication number: 20120059049
    Abstract: The present invention provides methods and kits for diagnosing and treating glaucoma.
    Type: Application
    Filed: October 26, 2011
    Publication date: March 8, 2012
    Applicants: NORTH TEXAS HEALTH SCIENCES CENTER, UNIVERSITY OF, NOVARTIS AG
    Inventors: Abbot F. CLARK, Robert J. WORDINGER
  • Patent number: 8119642
    Abstract: A family of structurally rigid dopamine D3 receptor selective ligands is described. The family of structurally rigid dopamine D3 receptor selective ligands has the formula wherein A is cis or trans —CH?CH—, —C?C—, or cyclohexyl. B is cis or trans —CH?CH— or absent. R1 represents an optionally substituted phenyl group, wherein said substituents are selected from the group consisting of: hydrogen, halogen, amino, nitro, hydroxyl, alkoxy, alkyl, acyl and pyridyl, and said substitution may occur at any of the ortho, meta, or para positions, or R1 represents a heteroaromatic ring. A preferred heteroaromatic ring is indole, quinoxoline, pyridyl, pyrimidyl, or imidazole. R2 and R3 may be independently hydrogen or a halogen, or R2 alone may be C1, C2, or C3 alkoxy, and m is 1 or 2, and n is 0, 1, or 2.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: February 21, 2012
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, University of North Texas Health Science Center at Fort Worth
    Inventors: Amy Newman, Peter Grundt, Robert R. Luedtke
  • Publication number: 20120040914
    Abstract: A method of enhancing the effectiveness of a chemotherapeutic agent, such as Temozolomide (TMZ), or ionizing radiation against glioblastoma is described in the present invention. The method comprises targeting putative membrane androgen receptor (termed mAR) in glioma cells to enhance the cytotoxic effects of a chemotherapeutic agent or ionizing radiation while simultaneously affording protection to neighboring neurons.
    Type: Application
    Filed: August 11, 2011
    Publication date: February 16, 2012
    Applicant: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH
    Inventors: MEHARVAN SINGH, Adrienne Badeaux, Niki Mirshams
  • Patent number: 8063013
    Abstract: The present invention provides methods and kits for diagnosing and treating glaucoma.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: November 22, 2011
    Assignees: Novartis AG, University of North Texas Health Science Center
    Inventors: Abbot F. Clark, Robert J. Wordinger
  • Publication number: 20110207614
    Abstract: The present invention provides partially fluorescent nanoparticles and methods of making and using the partially fluorescent nanoparticle having a nanoparticle with a matrix and a fluorescent dye dispersed in or about the matrix, wherein at least a portion of the fluorescent dye has been anisotropically bleached.
    Type: Application
    Filed: February 17, 2011
    Publication date: August 25, 2011
    Applicant: University of North Texas Health Science Center at Fort Worth
    Inventors: Zygmunt Gryczynski, Ignacy Gryczynski, Rafal Luchowski, Julian Borejdo
  • Patent number: 7956989
    Abstract: The present invention includes a microscope and a method for using the microscope for single molecule with reduced photobleaching of a fluorophore (20) that includes a light translucent material (16); a metal layer (18) disposed on the light translucent material (16); a medium (15) disposed on the metal layer (18), the medium (15) having one or more fluorophores (20) capable of binding a target analyte (e.g.
    Type: Grant
    Filed: January 22, 2008
    Date of Patent: June 7, 2011
    Assignee: University of North Texas Health Science Center at Fort Worth
    Inventors: Zygmunt Gryczynski, Ignacy Gryczynski, Nils Calander, Julian Borejdo
  • Publication number: 20110089317
    Abstract: The present invention describes the development of thin film calibration strips for microscopy/spectroscopy systems and a simple method/routine to conduct instrument calibration using partially (uniaxially) oriented strip to calibrate microscopy system without the prior knowledge of exact polarization of the strip. The invention describes results from studies including a styryl derivative (LDS 798) embedded in poly(vinyl alcohol) (PVA) film. These films were progressively stretched up to 8 folds. Vertical and horizontal components of absorptions and fluorescence were measured and dichroic ratios were determined for different film stretching ratios. The stretched films have high polarization values for isotropic excitation. The isotropic and stretched PVA films doped with LDS 798 can be used as etalons in near infra red (NIR) spectroscopic measurements.
    Type: Application
    Filed: October 21, 2010
    Publication date: April 21, 2011
    Applicant: University of North Texas Health Science Center at Forth Worth
    Inventors: Ignacy Gryczynski, Zygmunt Gryczynski, Rafal Luchowski, Julian Borejdo
  • Publication number: 20100290982
    Abstract: The present invention includes compositions and methods of making an activated polymeric nanoparticle for targeted drug delivery that includes a biocompatible polymer and an amphiphilic stabilizing agent non-covalently associated with a spacer compound that includes at least one electrophile that selectively reacts with any nucleophilic on a targeting agent and places the targeting agent on the exterior surface of a biodegradable nanoparticle, wherein an active agent is encapsulated in or about the nanoparticle.
    Type: Application
    Filed: April 23, 2010
    Publication date: November 18, 2010
    Applicant: University of North Texas Health Science Center at Fort Worth
    Inventors: Amalendu Prakash Ranjan, Anindita Mukerjee, Jamboor K. Vishwanatha
  • Publication number: 20100204086
    Abstract: The present invention provides methods and kits for diagnosing and treating glaucoma.
    Type: Application
    Filed: April 23, 2010
    Publication date: August 12, 2010
    Applicants: ALCON, INC., NORTH TEXAS HEALTH SCIENCES CENTER, UNIVERSITY OF
    Inventors: Abbot F. CLARK, Robert J. WORDINGER
  • Patent number: 7744873
    Abstract: The present invention provides methods and kits for diagnosing and treating glaucoma.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: June 29, 2010
    Assignees: Alcon, Inc., University of North Texas Health Science Center
    Inventors: Abbot F. Clark, Robert J. Wordinger
  • Publication number: 20090269281
    Abstract: The present invention includes compositions and methods for treating a patient with cardiac hypertrophy by providing the patient with an effective amount of a Calmodulin kinase kinase inhibitor that is sufficient to treat cardiac hypertrophy.
    Type: Application
    Filed: September 9, 2008
    Publication date: October 29, 2009
    Applicant: University of North Texas Health Science Center at Fort Worth
    Inventors: Stephen R. Grant, Thomas G. Valencia
  • Patent number: 7605259
    Abstract: A family of structurally rigid dopamine D3 receptor selective ligands is described. The family of structurally rigid dopamine D3 receptor selective ligands has the formula wherein A is cis or trans —CH?CH—, —C?C—, or cyclohexyl. B is cis or trans —CH?CH— or absent. R1 represents an optionally substituted phenyl group, wherein said substituents are selected from the group consisting of: hydrogen, halogen, amino, nitro, hydroxyl, alkoxy, alkyl, acyl and pyridyl, and said substitution may occur at any of the ortho, meta, or para positions, or R1 represents a heteroaromatic ring. A preferred heteroaromatic ring is indole, quinoxoline, pyridyl, pyrimidyl, or imidazole. R2 and R3 may be independently hydrogen or a halogen, or R2 alone may be C1, C2, or C3 alkoxy, and m is 1 or 2, and n is 0, 1, or 2.
    Type: Grant
    Filed: September 15, 2003
    Date of Patent: October 20, 2009
    Assignee: University of North Texas Health Science Center at Fort Worth
    Inventors: Amy Newman, Peter Grundt, Robert R. Luedtke
  • Publication number: 20090218516
    Abstract: The present invention includes methods for ratiometric detection of analytes by surface plasmon coupled emission detection that includes disposing a target on the metal layer of a surface plasmon resonance detection system; coupling a first analyte to a first fluorescent dye and a second analyte to a second fluorescent dye; contacting the first and second analytes to the target on the surface plasmon resonance detection system; and measuring the intensity of a first and a second surface plasmon resonance enhanced fluorescence emission ring, wherein the first and second rings, respectively, quantitatively represents the amount of first and second analyte within 50 nanometers of the metal surface.
    Type: Application
    Filed: January 20, 2009
    Publication date: September 3, 2009
    Applicant: University of North Texas Health Science Center at Fort Worth
    Inventors: Zygmunt Gryczynski, Ignacy Gryczynski, Evgenia Matveeva, Julian Borejdo